Association of Serum EPCA-2 Level with Prostate Cancer in Chinese Han Population

Overview

Journal Int J Clin Exp Pathol

Specialty Pathology

Date 2015 Oct 15

PMID 26464694

Citations 3

Authors

Lei Wang

Ling Ma

Xinli Wang

Bing Li

Shan Guo

Qingdong Qiao

Affiliations

Soon will be listed here.

Abstract

Background: Early prostate cancer antigen 2 (EPCA-2), a kind of nuclear matrix protein, may relate to prostate cancer. However, the association of EPCA-2 level in serum with prostate diseases has not been clarified in Chinese Han population.

Methods: EPCA-2 and prostate-specific antigen (PSA) levels in serum were detected by enzyme linked immunosorbent assay in 116 patients with prostate cancer (PCa), 342 patients with benign prostatic hyperplasia (BPH), and 174 healthy controls (Control) in Chinese population. Associations of serum EPCA-2 and PSA level with prostate diseases were analyzed by ANOVA. Comparison of diagnostic effect for prostate cancer between EPCA-2 and PSA was evaluated by Receiver Operator Curve, Chi-square test, and others.

Results: Serum EPCA-2 and PSA levels in PCa group were significantly higher than BPH and Control group (EPCA-2: F=200.05, P<0.01; PSA: F=210.65, P<0.01). However, EPCA-2 levels in the prostate cancers with different pathological grade were no significant difference. Furthermore, for detection of prostate cancer, EPCA-2 had a sensitivity of 81.9% and a specificity of 87.6%.

Conclusions: Serum EPCA-2 could be used as a potential serological marker to diagnose prostate cancer in Chinese Han population, which was more specific than PSA and did not associate with pathological grades of prostate cancer.

Citing Articles

Biomarkers That Differentiate Benign Prostatic Hyperplasia from Prostate Cancer: A Literature Review.

McNally C, Ruddock M, Moore T, McKenna D Cancer Manag Res. 2020; 12:5225-5241.

PMID: 32669872 PMC: 7335899. DOI: 10.2147/CMAR.S250829.

Delivery Of Curcumin Nanoliposomes Using Surface Modified With CD133 Aptamers For Prostate Cancer.

Ma Q, Qian W, Tao W, Zhou Y, Xue B Drug Des Devel Ther. 2019; 13:4021-4033.

PMID: 31819373 PMC: 6886545. DOI: 10.2147/DDDT.S210949.

Analysis of differentially expressed genes, clinical value and biological pathways in prostate cancer.

He Z, Tang F, Lu Z, Huang Y, Lei H, Li Z Am J Transl Res. 2018; 10(5):1444-1456.

PMID: 29887958 PMC: 5992552.

References

Paul B, Dhir R, Landsittel D, Hitchens M, Getzenberg R . Detection of prostate cancer with a blood-based assay for early prostate cancer antigen. Cancer Res. 2005; 65(10):4097-100. DOI: 10.1158/0008-5472.CAN-04-4523. View

Eliasziw M, Donner A . Application of the McNemar test to non-independent matched pair data. Stat Med. 1991; 10(12):1981-91. DOI: 10.1002/sim.4780101211. View

Thompson I, Pauler D, Goodman P, Tangen C, Lucia M, Parnes H . Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004; 350(22):2239-46. DOI: 10.1056/NEJMoa031918. View

Benson M, Whang I, Pantuck A, Ring K, Kaplan S, Olsson C . Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol. 1992; 147(3 Pt 2):815-6. DOI: 10.1016/s0022-5347(17)37393-7. View

Zhao R, Huang Y, Cheng G, Liu J, Shao P, Qin C . Developing a follow-up strategy for patients with PSA ranging from 4 to 10 ng/ml via a new model to reduce unnecessary prostate biopsies. PLoS One. 2014; 9(9):e106933. PMC: 4182133. DOI: 10.1371/journal.pone.0106933. View

McVary K, Roehrborn C, Avins A, Barry M, Bruskewitz R, Donnell R . Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011; 185(5):1793-803. DOI: 10.1016/j.juro.2011.01.074. View

Saribacak A, Yilmaz H, Ciftci S, Ustuner M, Ozkan L, Ozkan T . The role of empiric antibiotic treatment in preventing unnecessary prostate biopsies in asymptomatic patients with PSA levels between 4 and 10 ng/ml. Int J Clin Exp Med. 2014; 7(8):2230-5. PMC: 4161573. View

Zhao Z, Ma W, Zeng G, Qi D, Ou L, Liang Y . Serum early prostate cancer antigen (EPCA) level and its association with disease progression in prostate cancer in a Chinese population. PLoS One. 2011; 6(5):e19284. PMC: 3086914. DOI: 10.1371/journal.pone.0019284. View

Dhir R, Vietmeier B, Arlotti J, Acquafondata M, Landsittel D, Masterson R . Early identification of individuals with prostate cancer in negative biopsies. J Urol. 2004; 171(4):1419-23. DOI: 10.1097/01.ju.0000116545.94813.27. View

10.

Jemal A, Siegel R, Xu J, Ward E . Cancer statistics, 2010. CA Cancer J Clin. 2010; 60(5):277-300. DOI: 10.3322/caac.20073. View

11.

Li J, White N, Zhang Z, Rosenzweig J, Mangold L, Partin A . Detection of prostate cancer using serum proteomics pattern in a histologically confirmed population. J Urol. 2004; 171(5):1782-7. DOI: 10.1097/01.ju.0000119823.86393.49. View

12.

Komatsu K, Wehner N, Prestigiacomo A, Chen Z, Stamey T . Physiologic (intraindividual) variation of serum prostate-specific antigen in 814 men from a screening population. Urology. 1996; 47(3):343-6. DOI: 10.1016/s0090-4295(99)80450-6. View

13.

Inahara M, Suzuki H, Kojima S, Komiya A, Fukasawa S, Imamoto T . Improved prostate cancer detection using systematic 14-core biopsy for large prostate glands with normal digital rectal examination findings. Urology. 2006; 68(4):815-9. DOI: 10.1016/j.urology.2006.05.010. View

14.

Bazinet M, Meshref A, Trudel C, Aronson S, Peloquin F, Nachabe M . Prospective evaluation of prostate-specific antigen density and systematic biopsies for early detection of prostatic carcinoma. Urology. 1994; 43(1):44-51; discussion 51-2. DOI: 10.1016/s0090-4295(94)80260-2. View

15.

Hasegawa Y, Oyama N, Nagase K, Fujibayashi Y, Furukawa T, Murayama Y . Monoclonal antibody RM2 as a potential ligand for a new immunotracer for prostate cancer imaging. Nucl Med Biol. 2012; 39(7):944-7. DOI: 10.1016/j.nucmedbio.2012.05.008. View

16.

Uetsuki H, Tsunemori H, Taoka R, Haba R, Ishikawa M, Kakehi Y . Expression of a novel biomarker, EPCA, in adenocarcinomas and precancerous lesions in the prostate. J Urol. 2005; 174(2):514-8. DOI: 10.1097/01.ju.0000165154.41159.b1. View

17.

Catalona W, Smith D, Ratliff T, Dodds K, Coplen D, Yuan J . Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991; 324(17):1156-61. DOI: 10.1056/NEJM199104253241702. View

18.

Fluss R, Faraggi D, Reiser B . Estimation of the Youden Index and its associated cutoff point. Biom J. 2005; 47(4):458-72. DOI: 10.1002/bimj.200410135. View

19.

Leman E, Getzenberg R . Nuclear structure as a source of cancer specific biomarkers. J Cell Biochem. 2007; 104(6):1988-93. PMC: 4281772. DOI: 10.1002/jcb.21363. View

20.

Rehman I, Azzouzi A, Catto J, Allen S, Cross S, Feeley K . Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer: a pilot study. Urology. 2004; 64(6):1238-43. DOI: 10.1016/j.urology.2004.06.063. View